A5075162505- Pulmonary Hypertension Research and Treatments
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Cardiovascular Function and Risk Factors
- Asthma and respiratory diseases
- Respiratory Support and Mechanisms
- Heart Failure Treatment and Management
- Medical Imaging and Pathology Studies
- Inhalation and Respiratory Drug Delivery
- Cardiovascular Issues in Pregnancy
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Neonatal Respiratory Health Research
- Peptidase Inhibition and Analysis
- Vascular Anomalies and Treatments
- Cardiovascular, Neuropeptides, and Oxidative Stress Research
- Renin-Angiotensin System Studies
- Cancer-related gene regulation
- Tracheal and airway disorders
- Respiratory and Cough-Related Research
- Liver Disease and Transplantation
- Nitric Oxide and Endothelin Effects
- Pediatric health and respiratory diseases
- Eosinophilic Disorders and Syndromes
- Soft tissue tumors and treatment
- Whipple's Disease and Interleukins
- Cardiovascular Syncope and Autonomic Disorders
Hospital Montecelo
1993-2024
Servicio Gallego de Salud
2024
Complejo Hospitalario de Pontevedra
2012-2022
Complexo Hospitalario Universitario A Coruña
2015-2022
Universidade de Vigo
2014
Hospital Universitario Dexeus
2014
We aimed to evaluate the accuracy of baseline exhaled nitric oxide fraction ( F eNO ) recognise individuals with difficult-to-treat asthma who have potential achieve control a guideline-based stepwise strategy. 102 consecutive patients suboptimal underwent increase in treatment maximal fluticasone/salmeterol combination dose for 1 month. Then, those remained uncontrolled received oral corticosteroids an additional With this approach, 53 (52%) gained control. Those achieved were more likely...
Background Pulmonary arterial hypertension (PAH) is a rare and progressive vascular disorder characterized by increased pulmonary resistance right heart failure. The aim of this study was to analyze the Bone Morphogenetic Protein Receptor 2 (BMPR2), Activin A type II receptor like kinase 1 (ALK1/ACVRL1) potassium voltage-gated channel, shakerrelated subfamily, member 5 (KCNA5) genes in patients with idiopathic associated PAH. Correlation among pathogenic mutations clinical functional...
Pulmonary arterial hypertension (PAH) is a rare and progressive vascular disorder characterized by increased pulmonary resistance right heart failure. The aim of this study was to analyze 5'UTR region in canonical transient receptor potential isoform 6 (TRPC6) 3'UTR Angiotensin II type I (AGTR1) genes patients with idiopathic associated PAH. Correlation among mutations clinical functional parameters further analyzed.Analysis TRPC6 AGTR1 performed polymerase chain reaction (PCR) direct...
Abstract Pulmonary Arterial Hypertension (PAH) is a rare and fatal disease where knowledge about its genetic basis continues to increase. In this study, we used targeted panel sequencing in cohort of 624 adult pediatric patients from the Spanish PAH registry. We identified 11 variants ATP-binding Cassette subfamily C member 8 ( ABCC8 ) gene, most them with splicing alteration predictions. One patient also carried another variant SMAD1 gene (c.27delinsGTAAAG). performed an vitro biochemical...
Pulmonary arterial hypertension (PAH) is a rare vascular disorder characterized by capillary wedge pressure ≤ 15 mmHg and mean pulmonary ≥ 25 at rest. PAH can be idiopathic, heritable or associated with other conditions. The aim of this study was to analyze the Endoglin (ENG) gene assess influence c.572G > A (p.G191D) mutation in patients idiopathic PAH. correlation between pathogenic mutations clinical functional parameters further analyzed. Sixteen different changes ENG were found 44 out...
Pulmonary arterial hypertension is a progressive disease that causes the obstruction of precapillary pulmonary arteries and sustained increase in vascular resistance. The aim was to analyze functionally variants found BMPR2 gene establish genotype-phenotype correlation. mRNA expression studies were performed using pSPL3 vector, subcellular localization pEGFP-N1 vector luciferase assays pGL3-Basic vector. We have identified 30 27 55 patients. In 16 patients we detected pathogenic mutations....
Pulmonary Arterial Hypertension (PAH) is a rare and progressive disease with low incidence prevalence, elevated mortality. PAH characterized by increased mean pulmonary artery pressure. The aim of this study was to analyse patients combined mutations in BMPR2, ACVRL1, ENG KCNA5 genes establish genotype-phenotype correlation. Major were analysed polymerase chain reaction (PCR) direct sequencing. Genotype-phenotype correlation performed. Fifty-seven (28 idiopathic PAH, 29 associated group I)...
Purpose: The pharmacological treatment of chronic obstructive pulmonary disease (COPD) is largely based on inhaled bronchodilators. Inspiratory flow and lung deposition are key parameters to be considered in therapy; however, the relationship between these two parameters, patient specificities, suitability inhaler type for COPD management has not been fully addressed. present study follows a Delphi Panel methodology find expert consensus role inspiratory as decision factors therapy. Methods:...
Pulmonary Arterial Hypertension (PAH) is a rare disease caused by the obliteration of pulmonary arterioles, increasing vascular resistance and eventually causing right heart failure. Endothelin-1 (EDN1) vasoconstrictor peptide whose levels are indicators progression its pathway one most common targeted current treatments. We sequenced EDN1 untranslated regions small subset patients with PAH, predicted effect in silico, used luciferase assay different genotypes to analyze influence on gene...